BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 18217156)

  • 1. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.
    Lobo B; Finch C; Howard A; Minhas S
    Thromb Haemost; 2008 Jan; 99(1):208-14. PubMed ID: 18217156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin.
    Warkentin TE
    Thromb Haemost; 2008 Jan; 99(1):2-3. PubMed ID: 18217128
    [No Abstract]   [Full Text] [Related]  

  • 3. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.
    Grouzi E; Kyriakou E; Panagou I; Spiliotopoulou I
    Clin Appl Thromb Hemost; 2010 Dec; 16(6):663-7. PubMed ID: 19825921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.
    Blackmer AB; Oertel MD; Valgus JM
    Ann Pharmacother; 2009 Oct; 43(10):1636-46. PubMed ID: 19737996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
    Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
    Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.
    Efird LE; Kockler DR
    Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The approach to heparin-induced thrombocytopenia.
    Linkins LA; Warkentin TE
    Semin Respir Crit Care Med; 2008 Feb; 29(1):66-74. PubMed ID: 18302088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Fondaparinux in Patients With Suspected Heparin-Induced Thrombocytopenia.
    Snodgrass MN; Shields J; Rai H
    Clin Appl Thromb Hemost; 2016 Nov; 22(8):712-717. PubMed ID: 27179015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fondaparinux as a treatment option for heparin-induced thrombocytopenia.
    Papadopoulos S; Flynn JD; Lewis DA
    Pharmacotherapy; 2007 Jun; 27(6):921-6. PubMed ID: 17542773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia.
    Srinivasan AF; Rice L; Bartholomew JR; Rangaswamy C; La Perna L; Thompson JE; Murphy S; Baker KR
    Arch Intern Med; 2004 Jan; 164(1):66-70. PubMed ID: 14718324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience.
    Schindewolf M; Scheuermann J; Kroll H; Marzi I; Kaufmann R; Boehncke WH; Ludwig RJ; Lindhoff-Last E
    Thromb Res; 2012 Jan; 129(1):17-21. PubMed ID: 21741076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of fondaparinux early after mechanical aortic valve replacement in a patient with a history of heparin-induced thrombocytopenia.
    Willenborg KL
    Pharmacotherapy; 2014 Jun; 34(6):e55-9. PubMed ID: 24644124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HIT treatment in a cardiac surgery patient.
    Anna N; Boyan T; Kader MA; Catherine M; Matthias K
    Int J Cardiol; 2010 Oct; 144(3):405-7. PubMed ID: 19324432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful use of fondaparinux in a child with heparin-induced thrombocytopenia.
    Tokgoz H; Caliskan U; Demir M
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):769-71. PubMed ID: 22964766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation.
    Mahieu E; Claes K; Jacquemin M; Evenepoel P; Op De Beek K; Bogaert AM; Kuypers D; Verhamme P; Meijers B
    Artif Organs; 2013 May; 37(5):482-7. PubMed ID: 23461610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: an observational retrospective case-control study.
    Gettings EM; Brush KA; Van Cott EM; Hurford WE
    Crit Care; 2006; 10(6):R161. PubMed ID: 17109753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful treatment with fondaparinux in heparin-induced thrombocytopenia and thrombosis].
    Seculini Patiño CE; Pascualini MF; Tabares AH
    Medicina (B Aires); 2015; 75(5):307-10. PubMed ID: 26502466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed-onset heparin-induced thrombocytopenia type-2 during fondiparinux (Arixtra) therapy.
    Modi C; Satani D; Cervellione KL; Cervantes J; Gintautas J
    Proc West Pharmacol Soc; 2009; 52():5-7. PubMed ID: 22128408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HITlights: a career perspective on heparin-induced thrombocytopenia.
    Warkentin TE
    Am J Hematol; 2012 May; 87 Suppl 1():S92-9. PubMed ID: 22367928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.